Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT06504576

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06504576
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06504576. Randomized; no masking; primary purpose treatment. Start 2025-06-16 (actual); primary completion 2027-01-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage
Acronym
EPOCH
Condition
ICH - Intracerebral Hemorrhage
Intervention (Drug)
Pletaal 100mg/tab
Intervention (Procedure)
Conventional internal medicine treatment
Lead sponsor
National Taiwan University Hospital (class: other)

Record details

Record id
cardio:ct-nct06504576
Content hash
263580eaa347853415298fc30b1e10f29fcb19175c4dfe40756415364a97c3e5